

INVESTMENT AND SOVEREIGN RESEARCH March-10-2020 Lasco Distributors Limited (LASD) PLEASE SEE IMPORTANT DISCLOSURES & COPYRIGHT INFRINGEMENT IN THE APPENDIX

Executive Summary

Founded in 1988, LASCO Distributors Limited is now a market leading distribution company in Jamaica. LASD is comprised of two divisions: Consumer and Pharmaceutical. The company is well known for several innovations and product introductions, namely its flagship product LASCO Food Drink and LaSoy - a range of soy beverage products, Curves Sanitary Napkins, and the iCool range of water, flavoured water and juice drinks.

We recommend an overweight position in LASCO Distributors Limited as we believe the stock is currently trading below its fair value. We maintain our favourable opinion of the company and its moves to improve its distribution capacity, widen its sales network and improve margins.

Company Background

Founded in 1988, LASCO Distributors Limited is a major distribution company in Jamaica. Market positioning and the focus on satisfying consumer needs has helped LASD to become a market leader in several major categories in the industry. The company is well known for several innovations and product introductions, namely its flagship product LASCO Food Drink and LaSoy a range of soy beverage products, Curves Sanitary Napkins, the iCool range of water, flavoured water and juice drinks.

The company comprises of two divisions - the Consumer Division and the Pharmaceutical Division. The Consumer Division's major segments are food, beverage, personal care, baby care, adult incontinence and home care products. On the Pharmaceutical side, the supply network includes the distribution of ethical and over the counter (OTC) pharmaceutical products, animal health and equipment for major international brands, as well as the LASCO brand of generics - LASMED.

LASD distributes Unilever's home and personal care portfolio, with brands such as Breeze, Dove, St. Ives, Mistolin and Axe. LASD also distributes Salada's Jamaica Mountain Peak and Mountain Bliss 876 coffee as well as their range of teas. LASD's route to market covers all core channels which include supermarkets; wholesalers; small shops; schools; pharmacies; government institutions and health care facilities across Jamaica.



Lasco Distributors Limited (LASD)

Financial Performance – Nine Months ended December 31, 2019


Profitability

LASD reported a 7.3% or \$969.81M increase in revenues to \$14.3B for the nine months period ended Dec. 31, 2019. The Company recently launched its reduced sugar ICOOL beverage line and grape flavoured ICOOL water during the period which LASD noted has been doing well.

Cost of sales rose to \$11.48B, a 7.3% or \$777.17M increase year-over-year. As such, gross profits amounted to \$2.82B, also up 7.3% over the comparable period of the prior year. The gross profit margin held constant over the period at 19.7%. Other income amounted to \$70.73M, down 59.2% or \$102.59M from the prior year period.

Operating profit was down 5.7% to \$630.27M as operating expenses rose 6.0% to \$2.26B. Operating expenses as a percentage of revenues stood at 15.8%, a marginal improvement from 16.0% of revenues in the prior year period. Nevertheless, the operating profit margin fell from 5.0% in the prior year period to 4.4%.

Finance costs moved from \$474K to \$12.56M which contributed to the 7.5% decline in pre-tax profits to \$617.71M. However, LASD's ability to service its debt remained strong as the interest coverage ratio for the period stood at 50.2x. After taxes of \$60.21M, LASD reported a net profit of \$557.5M, which was down 10.2% from the prior year period. The net profit margin declined to 3.9% from 4.7% in the prior year period, driven by the decline in pre-tax earnings and an increase in the effective tax rate to 9.7%, up from 7.0% in the comparable period of the previous year.





Solvency & Liquidity

LASD's assets totalled \$9.49B as at Dec. 31, 2019, up 10.2% or \$879.54B from a year prior. Non-current assets increased by 15.3% or \$293.08M to \$2.21B as property, plant & equipment rose 7.1% to \$1.92B and 'financial assets' rose \$186.28M to \$202.63M. Current assets rose 8.8% or \$586.46M to \$7.28B, driven



Lasco Distributors Limited (LASD)

primarily by a 16.5% increase in receivables to \$3.26B and a 12.0% increase in cash & bank balances to \$1.23B. Inventories amounted to \$2.5B as well, up 0.9% year-over-year. Short-term investments of \$206.6M were up 4.4% year-over-year.

Total liabilities amounted to \$3.89B, up \$486.54M or 14.3% year-over-year. Driving this increase was a 15.4% or \$495.8M increase in payables, which closed the period at \$3.71B. Total debt was down 41.4% to \$113.33M as the outstanding balance of long-term loans fell 80.8% to \$33.33M. The current portion of long-term loans rose 300% to \$80.0M. Shareholders' equity amounted to \$5.6B, a 7.5% or \$393M improvement on its balance a year earlier. Retained earnings rose 7.9% to \$5.03B. As such, leverage, as measured by the debt-to-equity ratio, fell to 0.02x, down from 0.04x a year prior.

The cash ratio stood at 0.37x, down from 0.40x a year earlier, as current liabilities grew at a faster pace than cash and cash equivalents. The current ratio stood at 1.90x, which compares to 2.08x a year prior. Cash from operating activities amounted to \$845.44M, up from cash outflows of \$92.1M in the previous year period. This turn around was driven by the \$863.75M increase in payables, relative to a \$349.83M decline in the prior year period.

Outlook & Valuation

We anticipate a return to growth in net profits for the 2019/20FY following a 41% decline in the 2018/19FY due to the non-recurrence of \$273M in proceeds from the Pfizer award in the 2017/18FY. This increase is anticipated despite year-to-date performance being weaker than the previous year as we expect the company to recover from the loss made in the 4Q of the 2018/19FY. This growth is expected to continue into the 2020/21FY with revenues projected at \$20.2B with net profits of \$629.62M (EPS: \$0.18) as the company will begin to pay the full corporate tax rate.

We utilized the 1-year P/E average of 21.31x, which when applied to our forward EPS yielded a price of \$3.82. Shareholders' equity is seen closing the 2021FY at \$6.02B, which translates to book value of \$1.72. Utilizing the 1-year P/B average of 2.27x yields a price of \$3.90. Averaging these estimates gives us a fair value of \$3.86 per share, 29.5% higher than the closing price of \$2.98 on March 3, 2020.

4 | Page

INVESTMENT AND SOVEREIGN RESEARCH March-10-2020



Lasco Distributors Limited (LASD)



Shares of LASD are down 7.2% year-to-date and 19.5% year-over-year. The subpar performance of LASD's share price may be explained by the general downturn in the local market indices as well weak year-to-date financial performance. Shareholders may also be expressing pessimism around the chances of success in LASD's appeal of its J\$273M award in the Pfizer case, where LASD and Medimpex sought damages related to an injunction granted to Pfizer in 2005 as Pfizer claimed the two local firms violated its patents.

LASD had sought US\$490M from Pfizer and optimism around the case drove the stock price above \$7.00 per share but was ultimately awarded just J\$273M in a November 2017 Supreme Court ruling which it has since appealed. Shareholders may have anticipated a much higher pay-out and no longer believe the company will be successful in its efforts in a case that began in 2005 and as such have cooled their interest, leading to the stock trading below our estimate of its fair value.

Recommendation

We recommend an OUTPERFORM/OVERWEIGHT/BUY position in LASCO Distributors Limited as we believe the stock is currently trading below its fair value. We view the company's efforts to improve its distribution capacity, widen its sales network and continue to innovate its product line as favourable. Moderate inflation expectations should continue to support revenue growth and the company is expected to continue to show recovery in profitability. The Company is also expected to continue to benefit from its relationship with LASCO Manufacturing Limited as it serves as a distributor for its products. Growth prospects are tempered by the competitive nature of the distribution industry. LASD is most suitable for the medium to long-term investor with a medium to high-risk appetite as the distribution sector remains highly competitive.



Lasco Distributors Limited (LASD)

Abridged Financials

| J\$000 | Year Ended June 30 | | | | | % | | |
|---------------------------|--------------------|------------|------------|------------|------------|------------|------------|--------|
| | 2015 | 2016 | 2017 | 2018 | 2019 | 9M19 | 9M20 | change |
| | | | | | | | | |
| Turnover | 11,146,892 | 14,549,098 | 15,803,329 | 16,269,083 | 18,130,689 | 13,330,780 | 14,300,588 | 7.3% |
| Operating Expenses | 1,531,113 | 1,984,020 | 2,363,076 | 2,487,376 | 2,979,036 | 2,131,201 | 2,259,380 | 6.0% |
| Operating Profit | 548,917 | 758,930 | 689,508 | 1,079,893 | 705,859 | 668,394 | 630,270 | -5.7% |
| Profit Before Taxation | 546,730 | 757,495 | 686,892 | 1,079,369 | 691,942 | 667,920 | 617,713 | -7.5% |
| Profit for the year | 546,730 | 716,751 | 609,678 | 1,003,879 | 597,781 | 620,853 | 557,499 | -10.2% |
| | | | | | | | | |
| Total Assets | 5,334,577 | 6,496,070 | 7,392,240 | 8,510,266 | 8,639,662 | 8,611,988 | 9,491,525 | 10.2% |
| Total Liabilities | 2,451,616 | 2,938,026 | 3,344,104 | 3,940,412 | 3,450,675 | 3,405,586 | 3,892,128 | 14.3% |
| Shareholder's Equity | 2,882,961 | 3,558,044 | 4,048,136 | 4,569,854 | 5,188,987 | 5,206,402 | 5,599,397 | 7.5% |
| | | | | | | | | |
| EPS (\$) | 0.16 | 0.20 | 0.17 | 0.29 | 0.17 | 0.18 | 0.16 | |
| Book Value per Share (\$) | 0.82 | 1.01 | 1.15 | 1.30 | 1.48 | 1.48 | 1.60 | |
| | | | | | | | | |
| Key Ratios | | | | | | | | |
| Gross profit margin | 18.0% | 18.3% | 18.6% | 19.5% | 19.6% | 19.7% | 19.7% | |
| Operating profit margin | 4.9% | 5.2% | 4.4% | 6.6% | 3.9% | 5.0% | 4.4% | |
| Net Margin | 4.9% | 4.9% | 3.9% | 6.2% | 3.3% | 4.7% | 3.9% | |
| Return on Average Equity | 20.7% | 22.3% | 16.0% | 23.3% | 12.3% | | | |
| Return on Average Assets | 11.5% | 12.1% | 8.8% | 12.6% | 7.0% | | | |
| Debt/Equity (x) | - | 0.00 | 0.06 | 0.09 | 0.06 | 0.04 | 0.02 | |

Source: http://www.Jamstockex.com, JMMB Investment & Research, Bloomberg, Company Financials



Lasco Distributors Limited (LASD)

APPENDIX

IMPORTANT DISCLOSURES

ABSTRACT—As a part of our new Portfolio Strategy we are recommending strict adherence to the following Portfolio Allocation **DEFINITIONS/RECOMMENDATIONS**.

<u>PLEASE NOTE</u> THAT NO INDIVIDUAL ASSET IN YOUR PORTFOLIO SHOULD HAVE A WEIGHTING GREATER THAN 5% UNLESS OTHERWISE RECOMMENDED BY YOUR PORTFOLIO MANAGER OR A SPECIFIC JMMB RESEARCH REPORT. CONSEQUENTLY THE FOLLOWING <u>DEFINITIONS</u> ARE PROVIDED FOR CLARITY.

OUTPERFORM/OVERWEIGHT/BUY—EXPOSURE TO THIS ASSET SHOULD BE UP TO 10% OF YOUR TOTAL PORTFOLIO HELD AT JMMB

MARKETPERFORM/HOLD/MARKETWEIGHT—EXPOSURE TO THE ASSET SHOULD BE EQUAL TO 5% OF YOUR TOTAL PORTFOLIO HELD AT JMMB.

UNDERPERFORM/UNDERWEIGHT— ADJUST EXPOSURE IN YOUR PORTFOLIO HELD AT JMMB TO BETWEEN 2.5% AND 4.9% FOR THIS PARTICULAR ASSET

STRONGLY UNDERPERFORM/UNDERWEIGHT—REDUCE EXPOSURE TO THIS ASSET TO BELOW 2.5% OF YOUR TOTAL PORTFOLIO HELD AT JMMB

SELL-REDUCE EXPOSURE IN YOUR PORTFOLIO TO ZERO (0%).

COPYRIGHT INFRINGEMENT

"Unless otherwise expressly stated, copyright or similar rights in all material in this research report (including graphical images) is owned, controlled or licensed by Jamaica Money Market Brokers Limited or its affiliates (JMMB) and is protected or covered by copyright, trade mark, intellectual property law and other proprietary rights. No part of this research report or the report in its entirety may be published, used, reproduced, distributed, displayed or copied for public or private use in any form including by any mechanical, photographic or electronic process (electronically, digitally on the Internet or World Wide

7 | Page

INVESTMENT AND SOVEREIGN RESEARCH March-10-2020

Lasco Distributors Limited (LASD)

Your Best Interest At Heart. Full Stop

Web, or over any network, or local area network or otherwise) without written permission from JMMB.

No part of this research report may be modified or changed or exploited or used in any way for derivative works, or offered for sale, or used to construct any kind of database or mirrored at any other location without the express written permission of JMMB.

Thank you for respecting our intellectual property rights."

The investments referred to in this report may not be suitable for you should consult your licensed investment advisor. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable to your individual circumstances or otherwise constitutes a personal recommendation to you.

Disclosure Under The Securities Act

This disclosure is being provided pursuant to section 39 of the Securities Act. This research report is prepared by Jamaica Money Market Brokers Limited (JMMB) and the information and views expressed are those of JMMB. JMMB is a subsidiary of the JMMB Group Limited (JMMBGL). Associated persons of JMMB include JMMBGL and its subsidiaries and affiliated companies, including JMMB Fund Managers Limited, a licensed securities dealer and manager of collective investment schemes.

As at the date of this report, JMMB and its affiliates, directors, officers, employees and other associated persons may from time to time buy or sell, or act as principal or agent in, the securities mentioned in this research report. JMMB or its affiliates, directors, officers and employees have no interest in or interest in the acquisition or disposal of the securities other than expressed above. No part of their compensation is or will be related to the recommendations or opinions in this report.